Harrow (HROW) shares soared 11.4% in the last trading session to close at $34.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.7% gain over the past four weeks.The sudden rise in the share price of Harrow can be attributed to the positive investor mindset regarding the continued sales growth of its innovative opthalmic pharmaceutical products in the North American market, which is expected to further boost shareholder value. ...

Astronics Corporation (ATRO) shares rallied 16.2% in the last trading session to close at $36.11. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.2% loss over the past four weeks.The latest uptick in ATRO’s share price can be attributed to a recent upgrade made in this stock’s rating. Notably, Truist Securities upgraded Astronics from Hold to Buy and raised its price target to $49.00 from $32.00. This comp ...

Group 1 - CRISPR Therapeutics AG (CRSP) has an average brokerage recommendation (ABR) of 1.88, indicating a consensus between Strong Buy and Buy based on 27 brokerage firms' recommendations [2] - Out of the 27 recommendations, 15 are classified as Strong Buy, accounting for 55.6%, while one is classified as Buy, accounting for 3.7% [2] - Despite the positive ABR, caution is advised as studies show limited success of brokerage recommendations in predicting stock price increases [5][10] Group 2 - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, with five Strong Buy recommendations for every Strong Sell [6][10] - The Zacks Rank, a proprietary stock rating tool, is highlighted as a more reliable indicator of near-term price performance, based on earnings estimate revisions [8][11] - The Zacks Consensus Estimate for CRISPR Therapeutics remains unchanged at -$5.54, suggesting the stock may perform in line with the broader market [13][14] Group 3 - The Zacks Rank for CRISPR Therapeutics is currently 3 (Hold), indicating a more cautious stance compared to the Buy-equivalent ABR [14] - The ABR is not always up-to-date, while the Zacks Rank reflects timely earnings estimate revisions, making it a more current indicator of future price movements [12]

Core Viewpoint - Western Alliance (WAL) is expected to report a quarterly earnings per share (EPS) of $2.02, marking a 15.4% increase year-over-year, with revenues projected at $848.1 million, reflecting an 8.5% increase compared to the same period last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 1.3% over the past 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Key Metrics Projections - Analysts predict a 'Net Interest Margin' of 3.4%, down from 3.6% in the same quarter last year [5]. - The estimated 'Efficiency Ratio' is 58.5%, compared to 62.3% in the same quarter of the previous year [5]. - 'Average Balance - Total interest earning assets' is forecasted to reach $79.16 billion, up from $73.87 billion year-over-year [5]. Income Projections - 'Total non-interest income' is expected to be $138.64 million, an increase from $115.20 million in the same quarter last year [6]. - 'Service charges and fees' are projected at $39.00 million, significantly higher than the $10.80 million reported a year ago [6]. - 'Net interest income' is anticipated to reach $689.27 million, compared to $656.60 million in the same quarter last year [7]. - 'Net gain on loan origination and sale activities' is expected to be $59.48 million, up from $46.80 million year-over-year [7]. - 'Other non-interest income' is projected at $15.06 million, compared to $8.10 million last year [8]. - 'Net loan servicing revenue' is expected to be $24.72 million, down from $38.10 million in the same quarter last year [8]. Stock Performance - Shares of Western Alliance have increased by 18.5% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4% [8].

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying stocks that can fulfill their growth potential is challenging due to associated risks and volatility [1] Group 1: Company Overview - Orion OYJ Unsponsored ADR (ORINY) is identified as a promising growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 5.2%, but projected EPS growth for this year is expected to be 30.2%, significantly higher than the industry average of 15.2% [4] Group 2: Financial Metrics - Orion OYJ's year-over-year cash flow growth is reported at 57.5%, which surpasses the industry average of 3.2% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 9.7%, compared to the industry average of 6.7% [6] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for Orion OYJ, with the Zacks Consensus Estimate for the current year increasing by 26.2% over the past month [8] - The combination of a Growth Score of B and a Zacks Rank 1 indicates that Orion OYJ is a potential outperformer and a solid choice for growth investors [10]

Global-e Online Ltd. (GLBE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked ...

Core Viewpoint - Airbus Group has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2][3]. - The recent upgrade for Airbus Group suggests an improvement in its earnings outlook, which could lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, with institutional investors using these estimates to assess fair value [5][7]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. Specifics on Airbus Group's Earnings - For the fiscal year ending December 2025, Airbus Group is expected to earn $1.82 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6.4% over the past three months [9]. Conclusion on Zacks Rating System - The Zacks rating system maintains a balanced approach, with only the top 5% of stocks receiving a "Strong Buy" rating, indicating superior earnings estimate revisions and potential for market-beating returns [10][11].

Core Viewpoint - Mizuho (MFG) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Mizuho suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell), and has a proven track record of performance [7]. - Stocks in the top 20% of Zacks-covered stocks, like Mizuho with its Zacks Rank 2, are positioned for potential market-beating returns [10]. Earnings Estimate Revisions for Mizuho - For the fiscal year ending March 2026, Mizuho is expected to earn $0.55 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 12.2% over the past three months [8].

FVCBankcorp (FVCB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power o ...

Lincoln Educational Services Corporation (LINC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimat ...